Latest Articlesddd
Seattle Genetics and Pieris pharmaceutical Collaboration Agreement Pieris Pharmaceuticals (PIRS) and Seattle Genetics (SGEN) signed a multi-program immuno-oncology collaboration …
Expected or not, we believe that the news announcing that the U.S. Food and Drug Administration …
Bristol-Myers Squibb (BMY) and Nektar Therapeutics (NKTR) Announce Global Development & Commercialization Collaboration for Nektar’s Product …
The Week in Review #17 A Wild Wild Week - The stock market looked as if …
Prohost Letter #417 Private Lessons - These lessons are overdue and we had to do this …
A Stanford research team investigating a new immunotherapy approach, which consists of injecting tiny amounts of two immuno-stimulating …
We postponed the Prohost Letter we planned to post this past Monday until the market’s fits come to …
Vertex (VRTX) announced the selection of two next-generation correctors, VX-659 and VX-445, to advance into Phase 3 development as part …
Yes, the title is real and correct and the condition is ASD. The US Food and …
ChemoCentryx (CCXI) develops new drugs for inflammatory, autoimmune diseases and cancers. The firm’s approach comprises targeting the chemokine …
Amgen (AMGN): Phase 3b results from LIBERTY study assessing the safety and efficacy of Aimovig™(erenumab) 140 mg in …
Celgene (CELG) and Juno (JUNO) announced the signing of a definitive merger agreement upon which Celgene has agreed to …
Acorda (ACOR) stock was up around 10% reaching over $28 in premarket trading. The stock is trading …
Juno Therapeutics’ (JUNO) stock price orbited the moon after-hours trading yesterday, rising 45%, following a wall street …
The Week in Review #16 More Exciting Rallies in Prohost Picks - The past week and …
Checkpoint inhibitors approved for a few firms as immunotherapy for cancer are increasingly demonstrating their superiority …
VERTEX From Europe, Vertex (VRTX) was informed that the European Commission has granted an extension of the Marketing …
Prohost Letter #416 Part 2 2017 - A YEAR OF BREAKTHROUGH TECHNOLOGIES, BREAKTHROUGH PRODUCTS, IMPROVEMENTS ON …
As part of its ongoing strategy to build an innovative pipeline beyond its two internally-discovered, commercially …
On Dec. 12, 2017, Denali Therapeutics (DNLI) announced the closing of its initial public offering of 15,972,221 shares …
We use cookies to ensure that we give you the best experience on our website. If you continue to use this site we will assume that you are happy with it. Accept Privacy policy
